Published in J Clin Endocrinol Metab on October 19, 2011
Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes (2013) 1.85
Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab (2012) 1.55
Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol (2012) 1.10
The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. Diabetes Care (2016) 1.04
Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr) (2012) 0.93
Incretin hormones as immunomodulators of atherosclerosis. Front Endocrinol (Lausanne) (2012) 0.86
Exendin-4 pretreated adipose derived stem cells are resistant to oxidative stress and improve cardiac performance via enhanced adhesion in the infarcted heart. PLoS One (2014) 0.84
Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents. Nephrol Dial Transplant (2015) 0.82
Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study. J Clin Endocrinol Metab (2012) 0.81
Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.81
Stress in obesity and associated metabolic and cardiovascular disorders. Scientifica (Cairo) (2012) 0.81
The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity. PLoS One (2013) 0.81
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest (2017) 0.81
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol (2014) 0.80
GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol (2016) 0.78
GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring) (2015) 0.78
Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes. Curr Diab Rep (2013) 0.78
Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. Basic Res Cardiol (2015) 0.78
Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice. PLoS One (2016) 0.77
Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? Diabetes Ther (2016) 0.77
Effects of Exendin-4 on human adipose tissue inflammation and ECM remodelling. Nutr Diabetes (2016) 0.76
Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies. Curr Diabetes Rev (2016) 0.75
Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma. Horm Cancer (2013) 0.75
Oral but not intravenous glucose acutely decreases circulating interleukin-6 concentrations in overweight individuals. PLoS One (2013) 0.75
Inflammation and incretins. Indian J Endocrinol Metab (2012) 0.75
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol (2017) 0.75
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes Care (2013) 0.75
Cardiovascular effects of incretin therapy in diabetes care. Metab Syndr Relat Disord (2014) 0.75
Extrapancreatic effects of incretin hormones: evidence for weight-independent changes in morphological aspects and oxidative status in insulin-sensitive organs of the obese nondiabetic Zucker rat (ZFR). Physiol Rep (2016) 0.75
Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia. J Inflamm Res (2015) 0.75
G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts. PLoS One (2016) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Inflammation and metabolic disorders. Nature (2006) 33.33
TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest (2006) 17.49
Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med (1997) 14.51
A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res (1991) 13.54
Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem (1999) 7.38
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 7.25
Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation (2004) 3.17
SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem (2001) 3.09
Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab (2001) 3.05
Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes (2003) 3.00
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol (2009) 2.94
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes (2009) 2.58
Oxidative damage to DNA in diabetes mellitus. Lancet (1996) 2.54
Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes (2010) 2.34
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab (2001) 2.24
The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes (2002) 1.96
Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (1999) 1.86
Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology (2000) 1.56
Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia (2010) 1.46
Toll-like receptor 4 in atherosclerosis. J Cell Mol Med (2007) 1.44
JNK: a new therapeutic target for diabetes. Curr Opin Pharmacol (2003) 1.42
Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract (2007) 1.35
Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun (2009) 1.27
Toll-like receptors as sensors of pathogens. Pediatr Res (2001) 1.26
Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care (2010) 1.23
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care (2010) 1.21
Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther (2010) 1.21
Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem (2003) 1.20
Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol (2011) 1.15
Serum amyloid A: the "other" inflammatory protein. Curr Atheroscler Rep (2006) 1.14
Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism (2000) 1.11
Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression. Neoplasia (2001) 1.07
Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations. Endocr Pract (2011) 1.01
Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther (2011) 0.95
Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann N Y Acad Sci (2008) 0.94
Exenatide. Drugs Today (Barc) (2005) 0.83
Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation (2004) 3.17
Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes (2003) 3.00
Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab (2004) 2.93
Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care (2009) 2.83
Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab (2004) 2.36
Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke (2005) 2.24
Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. Am J Clin Nutr (2010) 1.85
Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care (2010) 1.61
Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care (2010) 1.60
Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr (2004) 1.57
Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab (2012) 1.55
The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol (2013) 1.54
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF TESTOSTERONE AND CARDIOVASCULAR RISK. Endocr Pract (2015) 1.52
Sequence relationships among C. elegans, D. melanogaster and human microRNAs highlight the extensive conservation of microRNAs in biology. PLoS One (2008) 1.49
An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab (2010) 1.48
Acute modulation of toll-like receptors by insulin. Diabetes Care (2008) 1.46
Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation (2004) 1.46
Orange juice or fructose intake does not induce oxidative and inflammatory response. Diabetes Care (2007) 1.46
Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol (2009) 1.43
Rosiglitazone, thiazolidinediones and atherosclerosis. Atherosclerosis (2010) 1.41
Prolonged reactive oxygen species generation and nuclear factor-kappaB activation after a high-fat, high-carbohydrate meal in the obese. J Clin Endocrinol Metab (2007) 1.38
Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab (2002) 1.35
Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract (2007) 1.35
A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab (2011) 1.35
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care (2002) 1.35
Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab (2004) 1.34
Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab (2011) 1.33
Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab (2003) 1.25
Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol (2006) 1.23
Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr (2002) 1.19
Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care (2006) 1.18
Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells. Metabolism (2004) 1.17
Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care (2003) 1.16
Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol (2011) 1.15
Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab (2003) 1.13
Testosterone concentration in young patients with diabetes. Diabetes Care (2008) 1.11
Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care (2006) 1.11
Anti-inflammatory effects of insulin. Curr Opin Clin Nutr Metab Care (2007) 1.10
Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab (2006) 1.04
Suppressive effect of insulin infusion on chemokines and chemokine receptors. Diabetes Care (2010) 1.03
Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens (2007) 1.01
Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations. Endocr Pract (2011) 1.01
Comparative evaluation of adjunctive oral irrigation in diabetics. J Clin Periodontol (2002) 1.00
Prediction of adverse outcomes by blood glucose level after endovascular therapy for acute ischemic stroke. J Neurosurg (2011) 1.00
Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med (2008) 1.00
Reduction in inflammation and the expression of amyloid precursor protein and other proteins related to Alzheimer's disease following gastric bypass surgery. J Clin Endocrinol Metab (2012) 0.99
A high-carbohydrate diet in the immediate postnatal life of rats induces adaptations predisposing to adult-onset obesity. J Endocrinol (2008) 0.98
Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance. Exp Mol Med (2010) 0.96
Insulin increases reendothelialization and inhibits cell migration and neointimal growth after arterial injury. Arterioscler Thromb Vasc Biol (2009) 0.95
Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism (2002) 0.95
Cardiovascular benefits of exogenous insulin. J Clin Endocrinol Metab (2012) 0.95